Sara Vesely to ADAM Proteins
                            
                            
                                This is a "connection" page, showing publications Sara Vesely has written about ADAM Proteins.
                            
                            
                            
                                
                                    
                                            
    
        
        
        
            Connection Strength
            
                
            
            1.626
         
        
        
     
 
    
        
        - 
            Blood group O and black race are independent risk factors for thrombotic thrombocytopenic purpura associated with severe ADAMTS13 deficiency. Transfusion. 2011 Oct; 51(10):2237-43.
            
            
                Score: 0.346
             
- 
            Life after acquired thrombotic thrombocytopenic purpura: morbidity, mortality, and risks during pregnancy. J Thromb Haemost. 2015 Jun; 13 Suppl 1:S216-22.
            
            
                Score: 0.115
             
- 
            Ribosomal and immune transcripts associate with relapse in acquired ADAMTS13-deficient thrombotic thrombocytopenic purpura. PLoS One. 2015; 10(2):e0117614.
            
            
                Score: 0.113
             
- 
            Increased urinary albumin excretion following recovery from thrombotic thrombocytopenic purpura due to acquired ADAMTS13 deficiency. Am J Kidney Dis. 2014 Aug; 64(2):317-8.
            
            
                Score: 0.107
             
- 
            Pregnancy outcomes following recovery from acquired thrombotic thrombocytopenic purpura. Blood. 2014 Mar 13; 123(11):1674-80.
            
            
                Score: 0.105
             
- 
            Children and adults with thrombotic thrombocytopenic purpura associated with severe, acquired Adamts13 deficiency: comparison of incidence, demographic and clinical features. Pediatr Blood Cancer. 2013 Oct; 60(10):1676-82.
            
            
                Score: 0.100
             
- 
            Decreasing frequency of plasma exchange complications in patients treated for thrombotic thrombocytopenic purpura-hemolytic uremic syndrome, 1996 to 2011. Transfusion. 2012 Dec; 52(12):2525-32; quiz 2524.
            
            
                Score: 0.093
             
- 
            Evidence for a role of anti-ADAMTS13 autoantibodies despite normal ADAMTS13 activity in recurrent thrombotic thrombocytopenic purpura. Haematologica. 2012 Feb; 97(2):297-303.
            
            
                Score: 0.090
             
- 
            Survival and relapse in patients with thrombotic thrombocytopenic purpura. Blood. 2010 Feb 25; 115(8):1500-11; quiz 1662.
            
            
                Score: 0.079
             
- 
            Lessons learned from the Oklahoma thrombotic thrombocytopenic purpura-hemolytic uremic syndrome registry. J Clin Apher. 2008; 23(4):129-37.
            
            
                Score: 0.069
             
- 
            ADAMTS13 activity in thrombotic thrombocytopenic purpura-hemolytic uremic syndrome: relation to presenting features and clinical outcomes in a prospective cohort of 142 patients. Blood. 2003 Jul 01; 102(1):60-8.
            
            
                Score: 0.049
             
- 
            Thrombotic thrombocytopenic purpura: from the bench to the bedside, but not yet to the community. Ann Intern Med. 2003 Jan 21; 138(2):152-3.
            
            
                Score: 0.049
             
- 
            Depression and cognitive impairment following recovery from thrombotic thrombocytopenic purpura. Am J Hematol. 2015 Aug; 90(8):709-14.
            
            
                Score: 0.029
             
- 
            The role of rituximab in the management of patients with acquired thrombotic thrombocytopenic purpura. Blood. 2015 Mar 05; 125(10):1526-31.
            
            
                Score: 0.028
             
- 
            Pulmonary involvement in patients with thrombotic thrombocytopenic purpura. Eur J Haematol. 2014 Feb; 92(2):156-63.
            
            
                Score: 0.026
             
- 
            Multiple major morbidities and increased mortality during long-term follow-up after recovery from thrombotic thrombocytopenic purpura. Blood. 2013 Sep 19; 122(12):2023-9; quiz 2142.
            
            
                Score: 0.025
             
- 
            Systemic infections mimicking thrombotic thrombocytopenic purpura. Am J Hematol. 2011 Sep; 86(9):743-51.
            
            
                Score: 0.022
             
- 
            Different disparities of gender and race among the thrombotic thrombocytopenic purpura and hemolytic-uremic syndromes. Am J Hematol. 2010 Nov; 85(11):844-7.
            
            
                Score: 0.021
             
- 
            Frequency and significance of HIV infection among patients diagnosed with thrombotic thrombocytopenic purpura. Clin Infect Dis. 2009 Apr 15; 48(8):1129-37.
            
            
                Score: 0.019
             
- 
            Cognitive deficits after recovery from thrombotic thrombocytopenic purpura. Transfusion. 2009 Jun; 49(6):1092-101.
            
            
                Score: 0.019
             
- 
            Clinical outcomes after platelet transfusions in patients with thrombotic thrombocytopenic purpura. Transfusion. 2009 May; 49(5):873-87.
            
            
                Score: 0.019
             
- 
            Sporadic bloody diarrhoea-associated thrombotic thrombocytopenic purpura-haemolytic uraemic syndrome: an adult and paediatric comparison. Br J Haematol. 2008 May; 141(5):696-707.
            
            
                Score: 0.018
             
- 
            The Oklahoma Thrombotic Thrombocytopenic Purpura-Hemolytic Uremic Syndrome Registry: the Swiss connection. Eur J Haematol. 2008 Apr; 80(4):277-86.
            
            
                Score: 0.017
             
- 
            Overlapping features of thrombotic thrombocytopenic purpura and systemic lupus erythematosus. South Med J. 2007 May; 100(5):512-4.
            
            
                Score: 0.016
             
- 
            The incidence of thrombotic thrombocytopenic purpura-hemolytic uremic syndrome: all patients, idiopathic patients, and patients with severe ADAMTS-13 deficiency. J Thromb Haemost. 2005 Jul; 3(7):1432-6.
            
            
                Score: 0.014
             
- 
            Severe deficiency of VWF-cleaving protease (ADAMTS13) activity defines a distinct population of thrombotic microangiopathy patients. Transfusion. 2004 Feb; 44(2):146-50.
            
            
                Score: 0.013
             
- 
            The Oklahoma Thrombotic Thrombocytopenic Purpura-Hemolytic Uremic Syndrome (TTP-HUS) Registry: a community perspective of patients with clinically diagnosed TTP-HUS. Semin Hematol. 2004 Jan; 41(1):60-7.
            
            
                Score: 0.013
             
- 
            Factor V Leiden: a genetic risk factor for thrombotic microangiopathy in patients with normal von Willebrand factor-cleaving protease activity. Blood. 2002 Jan 15; 99(2):437-42.
            
            
                Score: 0.011